CN1057008C - Application of theachrome in preparing medicine for viral myocarditis - Google Patents
Application of theachrome in preparing medicine for viral myocarditis Download PDFInfo
- Publication number
- CN1057008C CN1057008C CN97116711A CN97116711A CN1057008C CN 1057008 C CN1057008 C CN 1057008C CN 97116711 A CN97116711 A CN 97116711A CN 97116711 A CN97116711 A CN 97116711A CN 1057008 C CN1057008 C CN 1057008C
- Authority
- CN
- China
- Prior art keywords
- tea pigment
- treatment
- viral myocarditis
- tea
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses a new application of a tea pigment drug, namely the application of tea pigments in the preparation of drugs for treating viral myocarditis. No matter whether the tea pigments are used alone or the tea pigments are matched with other drugs, the tea pigments are prepared into drugs, health caring food or health caring drugs which have the effect of treating the viral myocarditis.
Description
The present invention relates to the new medicine use of tea pigment, be specifically related to the application of tea pigment in the medicine of preparation treatment viral myocarditis, belong to the field of Chinese medicines.
Tea pigment is the natural plant pigment that extracts from Folium Camelliae sinensis, is a kind of active pigment complex that the continuous oxidation of catechin forms in the tea polyphenols.Tea pigment is made up of theaflavin, thearubigins and abrownin.For the existing bibliographical information of the research of tea pigment.CN1074618A discloses tea pigment and production method thereof.This production process is, Folium Camelliae sinensis is through decocting extracting juice, and alkalization concentrates, and acidify adds alcohol reflux, and alcohol reflux liquid alkalizes and obtains the tea pigment crystallization, through vacuum drying, promptly gets this tea pigment.The ratio of theaflavin, thearubigins and the persevering sky of abrownin three can be used as medicinal in the tea pigment that makes with this method.Medical value report for tea pigment may be summarized to be reduction blood viscosity, blood fat reducing, cholesterol reducing, prevention and treatment cardiovascular disease.But up to the present, the relevant tea pigment of Shang Weijian is used for the treatment of the report of viral myocarditis.
The object of the invention has provided a kind of new pharmaceutical applications of tea pigment, i.e. the application of tea pigment in the medicine of preparation treatment viral myocarditis.
Viral myocarditis is behind the upper respiratory tract infection or the myocardium inflammation that occurs between infection period, shows as symptoms such as nervous, uncomfortable in chest, dizzy, precordialgia.Tea pigment of the present invention is used for the treatment of viral cardiac muscle and belongs to discovery first.
The extracting method of tea pigment of the present invention can extract according to known extraction process, the tea pigment that extracts according to following method preferably: (1) Folium Camelliae sinensis is by 1: 15-30 extraordinarily water after once or once above decoction extracting juice, fried liquid is used in the aqueous solution can produce OH
-Ionic chemical compound alkalizes, and regulates PH8-10, at the 1/4-10 that heats concentrated this alkaline solution to the original volume amount down less than 70 ℃, gets concentrated solution then; (2) concentrated solution transfers to PH3-6 with acid, and acidifying solution adds ethanol 1-10 volume doubly to be measured, and backflow 0.5-2 hour, gets alcohol reflux liquid; (3) alcohol reflux liquid is used in the aqueous solution and can produces OH
-Ionic chemical compound is adjusted to PH7-10, and post precipitation filters, and gets the tea pigment crystallization, and the tea pigment crystallization promptly gets the tea pigment product through vacuum drying.
Tea pigment of the present invention is a kind of medicament active composition, preparation process according to routine, can be main active ingredient with tea pigment, add usual excipients, flavoring agent, components such as disintegrating agent, antiseptic, lubricant, wetting agent, binding agent, solvent, thickening agent, solubilizing agent, make any conventional agent shape, as tablet, capsule, granule, oral liquid, injection etc.
Because the present invention discloses the effect of tea pigment treatment viral myocarditis first, therefore, tea pigment cooperated separately or with other components make medicament, so long as this medicament is used for the treatment of viral myocarditis, all belong to protection scope of the present invention.
Tea pigment of the present invention all has the effect of treatment viral myocarditis when making any dosage form.Any medicament if contain tea pigment in its component or only prepare patent medicine with the single composition of tea pigment, as long as indicate the effect with treatment viral myocarditis, then falls within protection scope of the present invention on signs such as its packing or description.
Tea pigment of the present invention is the natural plants Folium Camelliae sinensis that derives from medicine-food two-purpose; therefore; also tea pigment can be made health food or health care medicine; health food or health care medicine that tea pigment is made; if on signs such as its packing or description, indicate the effect that the treatment viral myocarditis is arranged, also fall into protection scope of the present invention.
Embodiment 1
Tea pigment 125 grams
Medical starch 875 grams
Above-mentioned component is gone into blender, and fully stirring is mixed, and is encapsulated with capsule machine, adorns 1 gram for every, makes 1000 of tea pigment capsules, and every capsules contains 125 milligrams of tea pigments.
Embodiment 2
Tea pigment 250 grams
2000 milliliters of distilled water
Stevioside 1 gram
Tea pigment is dissolved in the distilled water, and fully mixing adds stevioside, and stirring and evenly mixing is once more packed in the vial with can packing machine, and sterilization makes the tea pigment oral liquid.
Experimental example tea pigment treatment acute viral myocarditis 21 examples are observed
1 data and method
1.1 case selects to meet national myocarditis cardiomyopathy in 1987 diagnostic criteria.Promptly in upper respiratory tract infection (go up sense) back or during last sense, heart sympton occurs, nervous, uncomfortable in chest, dizzy, precordialgia, cardiac auscultation can be heard third heart sound, electrocardiogram can have ST-T to change or arrhythmia, the lab testing erythrocyte sedimentation rate is fast, anti-" 0 " positive, mucin, myocardium zymetology increase etc.21 examples are organized in treatment, male 5 examples, women 16 examples, 16～42 years old age, The median age 28.5 years old.Matched group 18 examples, male 6 examples, women 12 examples, 14～43 years old age, The median age 26.5 years old.
1.2 the observational technique patient is divided into 2 groups at random.The treatment group: (penicillin is received salt 8,000,000 IU, ribavirin injection 600mg and polarized solution intravenous injection, 1 time/d at conventional therapy; Ventricular premature contraction, mexiletine, artrial premature beat add uses verapamil) on the basis, add the tea pigment capsule that provides by the green pharmaceutical Co. Ltd in (Sino-foreign joint venture) Jiangxi is provided, day clothes 3 times, each 250mg, be 15 days the course of treatment.Matched group is surplus with the treatment group except that not adding the tea pigment capsule.
1.3 efficacy determination
The result evaluation standard:
Produce effects: the subjective symptoms of treatment during one week obviously improved, and apical region of heart third heart sound and premature beat disappear, and ECG ST-T changes recovers normal.
Take a turn for the better: the back subjective symptoms improvement of two week of treatment, apical region of heart third heart sound and premature beat disappear, and ECG ST-T changes more preceding improvement.
Invalid: when referring to that 2 weeks of treatment back check, subjective symptoms is not improved, and apical region of heart third heart sound and premature beat do not disappear, ECG ST-T.
2 results
2.1 short term effect sees Table 1.
Table 1 shows that the total effective rate of treatment group and matched group is respectively 100% and 83.3%, and the treatment group is apparently higher than matched group, and learning by statistics to handle has significant difference (P＜0.01).
Relatively a group produce effects (%) takes a turn for the better table 1 a liang group short term effect that (n=21) matched group 8 (44.4) 7 (38.9) 3 (16.7) 15 (83.3) is (n=18) for (%) invalid (%) total effective rate (%) treatment group 12 (57.1) 9 (42.9) 0 21 (100)
2.2 cardinal symptom, sign and ECG change see Table 2
It is 90.6% that cardinal symptom in 21 examples, sign and ECG change total effective rate are organized in treatment, and matched group is 72.0%, two group relatively highly significant meaning (P＜0.01).
Cardinal symptom, sign and ECG change before and after the table 2 liang group myocarditis patient treatment
A group ambition breast electrocardiogram aggregate efficiency
The early early short battle array chamber ST-T change of room of the vexed pain nodal tachycardia of Yun not throbbing with fear chamber, (%) controlling front 12 18 13 11 18 532 19 treats, (n=21) 232001003 is effective after group was controlled, (%) control front 9 16 11 10 18 320 18 photographs for 83.3 83.3 84.6 100 100 80.0 100 100 84.2 90.6 pairs, (n=18) 243121118 is effective after group was controlled, (%) 77.7 75.0 72.7 90.0 88.8 66.6 50.0 0 55.5 72.0
2.3 the microcirculatory change of first wall sees Table 3
By table 3 as seen, the form integrated value descends to some extent, the no significance difference opposite sex (P＞0.05), and blood fluidised form, loop week state, total mark value all significantly descend, significant differences (P＜0.01) is arranged, illustrate that tea pigment has better improvement effect to first wall microcirculation.
Relatively (X ± S) all state total marks of (n=21) project pipe loop form blood flow state loop are treated 0.75 ± 0.63 2.18 ± 1.01 1.81 ± 1.05 4.86 ± 1.21 P＞0.05＜0.01＜0.01＜0.01, preceding 0.96 ± 0.83 5.28 ± 1.16 2.8 ± 1.28 9.64 ± 2.28 treatment back to the nail fold microcirculation integrated value before and after table 3 treatment
2.4 this group of side effect case treatment cross-reference is not found any side effect.
3 discuss
This paper brief summary tea pigment capsule treatment viral myocarditis improves the symptom effective percentage and reaches 87.8%, and electrocardiogram improves effective percentage 92.8%.Tea pigment can reduce the irritability that infects the back sinuatrial node, and the sinus tachycardia that slows down patient's heart rate and inhibition ectopic rhythm promote the blood supply of Ischemic Heart, improve clinical symptoms, microcirculation improvement." blood circulation promoting and blood stasis dispelling, the logical resistance of a surname's numbness, aromatic herbs activating YANG, tonification regulating QI " is the rule of treatment according to the traditional Chinese medical science, tea pigment has the adjusting cardiac function, regulate and safeguard the myocardium oxidative metabolism and the energy equilibrium of supply and demand, improve myocardial ischemia, decreased heart rate, arrhythmia, the electrocardiogram ischemia is improved, and having no side effect, is the good medicine of a safe and effective treatment acute viral myocarditis, and use value is widely arranged.
Claims (3)
1, the application of tea pigment in the medicine of preparation treatment viral myocarditis.
2, the application of tea pigment in the health product of preparation treatment viral myocarditis.
3, tea pigment is in the Application in Food of preparation treatment viral myocarditis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97116711A CN1057008C (en) | 1997-08-08 | 1997-08-08 | Application of theachrome in preparing medicine for viral myocarditis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97116711A CN1057008C (en) | 1997-08-08 | 1997-08-08 | Application of theachrome in preparing medicine for viral myocarditis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1207918A CN1207918A (en) | 1999-02-17 |
| CN1057008C true CN1057008C (en) | 2000-10-04 |
Family
ID=5174050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN97116711A Expired - Fee Related CN1057008C (en) | 1997-08-08 | 1997-08-08 | Application of theachrome in preparing medicine for viral myocarditis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1057008C (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1074618A (en) * | 1993-01-01 | 1993-07-28 | 南昌洪婺名茶开发公司 | Tea pigment and production method thereof |
-
1997
- 1997-08-08 CN CN97116711A patent/CN1057008C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1074618A (en) * | 1993-01-01 | 1993-07-28 | 南昌洪婺名茶开发公司 | Tea pigment and production method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1207918A (en) | 1999-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100382839C (en) | Chinese-medicinal composition for treating coronary heart disease | |
| KR20100020461A (en) | A new use of traditional chinese medical composition | |
| CN1140279C (en) | Blood-cleaning pill | |
| CN102908513B (en) | Application of traditional Chinese medicine composition in medicine for treating arrhythmia | |
| CN100336534C (en) | Medicine for treating coronary heart disease and its preparation method | |
| CN103505612A (en) | Traditional Chinese medicine composition containing total flavonoids of sea-buckthorn and preparation method of composition | |
| CN1057008C (en) | Application of theachrome in preparing medicine for viral myocarditis | |
| CN1401365A (en) | Chinese health medicine | |
| CN101698050B (en) | Application of traditional Chinese medicine composite in preparing medicine treating paroxysmal atrial fibrillation | |
| CN102861232A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating hypertension | |
| CN102716231B (en) | A kind of Chinese medicine composition and application thereof for the treatment of brain injury and cerebral edema | |
| CN101637556B (en) | Pharmaceutical composition for treating heart disease and preparation method thereof | |
| CN106943390B (en) | Application of the Strychnos nux-vomica aglycon in preparation prevention or treatment antiarrhythmic medicament | |
| CN115429836B (en) | Traditional Chinese medicine preparation for treating arrhythmia | |
| CN1248684C (en) | Chinese medicine powder for curing cardiovascular disease and preparing method thereof | |
| CN107157970A (en) | Purposes of the aloe-emodin in prevention and treatment myocardial ischemia and antiarrhythmic medicament is prepared | |
| CN115300554B (en) | Traditional Chinese medicine preparation for promoting blood circulation to remove meridian obstruction and preparation method thereof | |
| CN101658568B (en) | Application of Chinese medicinal composition in preparing medicament for treating pulmonary heart disease | |
| CN102309675B (en) | Application of Chinese medicine composition in preparing medicines for treating sick sinus syndrome | |
| CN107551217B (en) | Formula of traditional Chinese medicine composition for treating chronic heart failure by promoting expression of sarcoplasmic reticulum calcium pump | |
| CN1850068A (en) | Medicinal composition for treating cardio-cerebral-vascular disease and its preparing method | |
| CN1064254C (en) | Application of theaflavine for preparing medicine for treating oral submucosa fibrous disease | |
| CN1065759C (en) | Application of tea pigments in preparation of medicine for cor pulmonale | |
| CN104940554A (en) | Chinese herbal composition for treating heart diseases | |
| CN104524313A (en) | Traditional Chinese medicine preparation for treating sick sinus syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |